Page 57 - Read Online

Page 10 of 10 Farlow et al. J Cancer Metastasis Treat 2019;5:18 I http://dx.doi.org/10.20517/2394-4722.2018.100

25. Ferris RL, Goncalves A, Baxi SS, Martens UM, Gauthier H, et al. LBA46 - an open-label, multicohort, phase 1/2 study in patients with
virus-associated cancers (CheckMate 358): safety and efficacy of neoadjuvant nivolumab in squamous cell carcinoma of the head and neck.
Ann Oncol 2017;28:v605-v49.
26. Colevas AD, Bedi N, Chang S, Nieves UYM, Chatterjee S, et al. A study to evaluate immunological response to PD-1 inhibition in
squamous cell carcinoma of the head and neck (SCCHN) using novel PET imaging with [18F]F-AraG. J Clin Oncol 2018;36:6050.
27. Bell RB, Duhen R, Leidner RS, Curti BD, Ballesteros-Merino C, et al. Neoadjuvant anti-OX40 (MEDI6469) prior to surgery in head and
neck squamous cell carcinoma. J Clin ONcol 2018;36:6011.
28. Shayan G, Kansy BA, Gibson SP, Srivastava RM, Bryan JK, et al. Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant
Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. Clin Cancer Res 2018;24:62-72.
29. Rego DF, Pavan LM, Elias ST, De Luca Canto G, Guerra EN. Effects of metformin on head and neck cancer: a systematic review. Oral
Oncol 2015;51:416-22.
30. Curry J, Johnson J, Tassone P, Vidal MD, Menezes DW, et al. Metformin effects on head and neck squamous carcinoma microenvironment:
Window of opportunity trial. Laryngoscope 2017;127:1808-15.
31. Schmitz S, Caballero C, Locati LD. Perspectives on window of opportunity trials in head and neck cancer: lessons from the EORTC
90111-24111-NOCI-HNCG study. Eur J Cancer 2018;104:219-23.
32. Spector ME, Farlow JL, Haring CT, Brenner JC, Birkeland AC. The potential for liquid biopsies in head and neck cancer. Discov Med
2018;25:251-7.
33. Baxi SS, Dunn LA, Burtness BA. Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck
squamous cell carcinoma. Oral Oncol 2016;62:147-8.
34. Hanna GJ, Adkins DR, Zolkind P, Uppaluri R. Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma. Oral
Oncol 2017;73:65-9.
35. Saada-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in
patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2017;28:1605-11.
36. Schmitz S, Duhoux F, Machiels JP. Window of opportunity studies: Do they fulfil our expectations? Cancer Treat Rev 2016;43:50-7.
37. Primdahl H, Nielsen AL, Larsen S, Andersen E, Ipsen M, et al. Changes from 1992 to 2002 in the pretreatment delay for patients with
squamous cell carcinoma of larynx or pharynx: a Danish nationwide survey from DAHANCA. Acta Oncol 2006;45:156-61.
38. Esserman LJ, Woodcock J. Accelerating identification and regulatory approval of investigational cancer drugs. JAMA 2011;306:2608-9.